ABL Diagnostics Société anonyme (ABLD.PA)
40 additional metrics available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | N/A | N/A | N/A | N/A | 0 | N/A |
| Operating profit | €m | ||||||||
| Net profit | €m | -0 | -0 | N/A | N/A | N/A | N/A | -0 | N/A |
| EPS reported | € | ||||||||
| Operating cashflow per share | € | ||||||||
| Capex per share | € | ||||||||
| FCF per share | € | ||||||||
| Free cash flow | €m | ||||||||
| Net debt | €m | ||||||||
| Book value equity | €m | ||||||||
| Book value per share | € | ||||||||
| Number of shares | m | ||||||||
| DPS (TTM paid) | € |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | ||||||||
| P/B LTM | x | ||||||||
| P/S LTM | x | ||||||||
| P/FCF LTM | x | ||||||||
| EV/EBITDA LTM | x | ||||||||
| EV/Sales LTM | x | ||||||||
| Earnings Yield LTM | % | ||||||||
| FCF Yield | % | ||||||||
| Quality | |||||||||
| ROE | % | ||||||||
| ROIC | % | ||||||||
| Operating margin | % | ||||||||
| Gross margin | % | ||||||||
| FCF/Sales | % | ||||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | ||||||||
| Sales Growth YoY | % | ||||||||
| Net Income Growth YoY | % | ||||||||
| FCF Growth | % | ||||||||
| Operating Profit Growth | % | ||||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | ||||||||
| Dividend Growth | % | ||||||||
| Payout Ratio | % | ||||||||
| FCF/Debt | x | ||||||||
| Net Debt/EBITDA | x | ||||||||
| EBIT/Net interest | x | ||||||||
| Net debt/market cap | % | ||||||||
| Net debt/Equity | % | ||||||||
| Gross debt/equity | % | ||||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022. The company is headquartered in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ABL Diagnostics Société anonyme (ABLD.PA)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, NGS library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as Etablissements Fauvet Girel and changed its name to ABL Diagnostics Société anonyme in April 2022. The company is headquartered in Woippy, France. ABL Diagnostics Société anonyme is a subsidiary of Advanced Biological Laboratories (ABL) S.A.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free